# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $33 to $29.
Canaccord Genuity analyst Caitlin Cronin maintains InMode (NASDAQ:INMD) with a Hold and lowers the price target from $21 to ...
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decrea...
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode (NASDAQ:INMD) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.44 by 27....
InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to th...